Assyro AI

Orange Book product · Brand (NDA)

MOTPOLY XR

LACOSAMIDE

Brand (NDA)NDA 216185RX AUCTA

At a glance

May 04, 2023

Approved

Brand (NDA)

Application

Not listed

TE code

6

Listed patents

Key dates

  1. Approval

    FDA approval date of this drug product.

    May 04, 2023

    3 yr 2 mo ago

  2. Today

  3. Patent 11337943 expires

    Listed drug product patent expiration.

    Jun 05, 2040

    in 14 yr 2 mo

  4. Patent 11337943 expires

    Listed drug product patent expiration.

    Jun 05, 2040

    in 14 yr 2 mo

  5. Patent 11883374 expires

    Listed drug product patent expiration.

    Jun 05, 2040

    in 14 yr 2 mo

  6. Patent 11883374 expires

    Listed drug product patent expiration.

    Jun 05, 2040

    in 14 yr 2 mo

  7. Patent 12042474 expires

    Listed drug product patent expiration.

    Jun 05, 2040

    in 14 yr 2 mo

  8. Patent 12042474 expires

    Listed drug product patent expiration.

    Jun 05, 2040

    in 14 yr 2 mo

Pharmaceutical detail

Active ingredient

LACOSAMIDE

Strength

100MG

Dosage form

CAPSULE, EXTENDED RELEASE

Route

ORAL

TE code

Not listed

Application

NDA 216185

Product number

001

Marketing status

RX

Reference listed drug (RLD)

Yes

Reference standard (RS)

No

Active-ingredient family

View full family

This is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.

Listed patents (6)

Patents listed in the FDA Orange Book for this product, with expiration date and patent type.
PatentExpiresInType
11337943Jun 05, 2040in 14 yr 2 mo
ProductU-3660
11337943Jun 05, 2040in 14 yr 2 mo
ProductU-3954
11883374Jun 05, 2040in 14 yr 2 mo
ProductU-3660
11883374Jun 05, 2040in 14 yr 2 mo
ProductU-3954
12042474Jun 05, 2040in 14 yr 2 mo
ProductU-3660
12042474Jun 05, 2040in 14 yr 2 mo
ProductU-3954
Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.